Correlation Between Kura Oncology and AnaptysBio

Can any of the company-specific risk be diversified away by investing in both Kura Oncology and AnaptysBio at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Kura Oncology and AnaptysBio into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Kura Oncology and AnaptysBio, you can compare the effects of market volatilities on Kura Oncology and AnaptysBio and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Kura Oncology with a short position of AnaptysBio. Check out your portfolio center. Please also check ongoing floating volatility patterns of Kura Oncology and AnaptysBio.

Diversification Opportunities for Kura Oncology and AnaptysBio

-0.34

Correlation Coefficient

Kura Oncology  AnaptysBio

Very good diversification

The 3 months correlation between Kura and AnaptysBio is -0.34. Overlapping area represents the amount of risk that can be diversified away by holding Kura Oncology and AnaptysBio in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on AnaptysBio and Kura Oncology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Kura Oncology are associated (or correlated) with AnaptysBio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of AnaptysBio has no effect on the direction of Kura Oncology i.e., Kura Oncology and AnaptysBio go up and down completely randomly.

Pair Corralation between Kura Oncology and AnaptysBio

Given the investment horizon of 90 days Kura Oncology is expected to under-perform the AnaptysBio. But the stock apears to be less risky and, when comparing its historical volatility, Kura Oncology is 2.04 times less risky than AnaptysBio. The stock trades about -0.08 of its potential returns per unit of risk. The AnaptysBio is currently generating about 0.12 of returns per unit of risk over similar time horizon. If you would invest  1,322  in AnaptysBio on December 29, 2024 and sell it today you would earn a total of  573.00  from holding AnaptysBio or generate 43.34% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Kura Oncology  vs.  AnaptysBio

Kura Oncology

Risk-Adjusted Performance

Very Weak

Over the last 90 days Kura Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

AnaptysBio

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in AnaptysBio are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite somewhat inconsistent basic indicators, AnaptysBio sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Kura Oncology and AnaptysBio

The main advantage of trading using opposite Kura Oncology and AnaptysBio positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Kura Oncology position performs unexpectedly, AnaptysBio can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AnaptysBio will offset losses from the drop in AnaptysBio's long position.

The idea behind Kura Oncology and AnaptysBio pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.